GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Valuation Rank

Synergy Pharmaceuticals (FRA:S90) Valuation Rank


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Synergy Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Valuation Rank
Comparable Companies
BOM:523620 OWCP XCNQ:ACG NSE:PARABDRUGS BOM:530317 WAR:SP1 XCNQ:RVV XCNQ:CIG MYHI BOM:524703 BOM:531173 XCNQ:VRT BOM:539938 XPAR:MLGML XCNQ:ASIA PCYN XMAU:GOLI.N0000 XCNQ:OSO BSPK XCNQ:EHC
Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Website
http://www.synergypharma.com
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.